List of high-quality authors
Xinmai Medical: Net profit is expected to increase by 33% to 38% in 2023].
Xinmai Medical announced that it expects to achieve a net profit attributable to owners of the parent company of 47,464 in 2023$840,000 to $49,249230,000 yuan, an increase of 11,776 compared with the same period last year (statutory disclosure data).$990,000 to $13,561380,000 yuan, an increase of 33% to 38% year-on-year.
Fenglong shares: the company will be suspended from the opening of the market on January 30].
Fenglong announced that the company's controlling shareholder and actual controller are planning the transfer of control, which is being negotiated, and there are still major uncertainties. Trading in the Company** and convertible corporate bonds (Fenglong Convertible Bonds) will be suspended from the market open on January 30, 2024 (Tuesday), and the suspension period is expected to be no more than 2 trading days. During the suspension period, the company's convertible corporate bonds are suspended from being converted into shares.
Ningbo Dongli: Net profit in 2023 is expected to drop by 85%-88%].
Ningbo Dongli announced its 2023 annual performance forecast, with a net profit attributable to shareholders of listed companies of 38 million yuan to 50 million yuan in the reporting period, a decrease of 85%-88% over the same period last year.
Weigang Technology: It is planned to repurchase shares with 15 million yuan to 30 million yuan
Weigang Technology announced that it intends to repurchase shares with 15 million yuan to 30 million yuan, and repurchase ** no more than 25 yuan shares.
Hualian Holdings: Net profit is expected to decrease by 81% year-on-year in 202364%-87.38%】
Hualian Holdings announced that it is expected to make a net profit of 55 million yuan and 80 million yuan in 2023, a decrease of 87 from the same period last year38%-81.64%。